| Identification | Back Directory | [Name]
CAD 31) | [CAS]
2071209-49-7 | [Synonyms]
CAD031
CAD 31)
CAD-031
(CAD031
Acetic acid, 2,?2,?2-?trifluoro-?, (2E)?-?1-?(2,?4-?dimethylphenyl)?-?2-?[[3-?(trifluoromethoxy)?phenyl]?methylene]?hydrazide | [Molecular Formula]
C18H14F6N2O2 | [MOL File]
2071209-49-7.mol | [Molecular Weight]
404.31 |
| Chemical Properties | Back Directory | [Boiling point ]
386.8±52.0 °C(Predicted) | [density ]
1.30±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
0.77±0.50(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
CAD031 is a derivative of the Alzheimer's disease (AD) targeting agent J147 (HY-13779) with neuroprotective and memory-enhancing properties. CAD031 enhances memory in mice, improves dendritic structure, and stimulates cell division in the germinal zone of the brain in aged mice. CAD031 is more active than J147 in human neural stem cell assays[1]. | [References]
[1] Prior M, et al. Selecting for neurogenic potential as an alternative for Alzheimer's disease drug discovery. Alzheimers Dement. 2016 Jun;12(6):678-86. DOI:10.1016/j.jalz.2016.03.016 |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|